Lauren M. Tyler
Lauren M. Tyler's purchase track record
Lauren M. Tyler has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/22/2026 | COR | $149K | +16.7% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Cencora Valuation and AI Impact: Analysts Debate Growth Prospects. Recent analyses debate whether Cencora is undervalued or if its raised guidance is already priced in, as the stock trades near its 52-week high and average analyst target. Other reports suggest the company's distribution model could benefit more from AI disruption than certain telehealth competitors. The stock is also compared to major pharmaceutical companies like AbbVie and Eli Lilly as market participants assess the healthcare sector.
Transaction History
| CNC | ▲ Buy | Grant | 482 | $0 | 9/30/2026 | View on chart |
| COR | ▲ Buy | Grant | 97 | $30K | 7/31/2026 | View on chart |
| CNC | ▲ Buy | Grant | 3,155 | $0 | 7/17/2026 | View on chart |
| CNC | ▲ Buy | Grant | 61 | $0 | 6/30/2026 | View on chart |
| COR | ▲ Buy | Open Market | 550 | $149K | 6/22/2026 | View on chart |
| COR | ▲ Buy | Grant | 99 | $30K | 5/1/2026 | View on chart |
| COR | ▲ Buy | Grant | 557 | $200K | 3/5/2026 | View on chart |
| COR | ▲ Buy | Grant | 84 | $30K | 1/30/2026 | View on chart |
| COR | ▲ Buy | Grant | 89 | $30K | 11/1/2025 | View on chart |
| COR | ▲ Buy | Grant | 105 | $30K | 8/1/2025 | View on chart |
| COR | ▲ Buy | Grant | 104 | $30K | 5/1/2025 | View on chart |
| COR | ▲ Buy | Grant | 789 | — | 3/6/2025 | View on chart |
| COR | ▲ Buy | Grant | 99 | $25K | 1/31/2025 | View on chart |
| COR | ▲ Buy | Grant | 107 | $25K | 11/1/2024 | View on chart |
| COR | ▲ Buy | Grant | 103 | $25K | 8/1/2024 | View on chart |
| COR | ▲ Buy | Grant | 110 | $25K | 5/1/2024 | View on chart |
| COR | ▲ Buy | Grant | 843 | — | 3/12/2024 | View on chart |
| COR | ▲ Buy | Grant | 106 | $0 | 2/1/2024 | View on chart |
| COR | ▲ Buy | Grant | 134 | $0 | 11/1/2023 | View on chart |
| COR | ▲ Buy | Grant | 480 | $0 | 11/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Centene Expands CHOICE Arrangements in Indiana, Ohio, Oklahoma
Centene has rolled out new benefit programs that support its CHOICE arrangements in Indiana, Ohio and Oklahoma, signaling a push to broaden its managed care footprint. Analysts note the company’s turnaround still has room to grow, and its target price remains well above the current level. The broader managed‑care landscape is also shifting, with UnitedHealth reporting higher margins but lower membership, a trend that may influence competitive dynamics.
Centene Expands CHOICE Arrangements in Indiana, Ohio, Oklahoma. Centene has rolled out new benefit programs that support its CHOICE arrangements in Indiana, Ohio and Oklahoma, signaling a push to broaden its managed care footprint. Analysts note the company’s turnaround still has room to grow, and its target price remains well above the current level. The broader managed‑care landscape is also shifting, with UnitedHealth reporting higher margins but lower membership, a trend that may influence competitive dynamics.